Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Restem-L
- Development stage
- Phase 1
- Lead developer
- Restem Group
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Restem-L is an allogeneic, immune-modulatory cell therapy composed of umbilical cord lining-derived stem cells (ULSC), also referred to as umbilical mesenchymal progenitor cells (UMPCs). Developed by Restem, LLC, the therapy is designed to modulate key inflammatory factors and reduce muscle degeneration. It is currently being investigated in clinical trials for the treatment of inflammatory myopathies, including dermatomyositis (DM) and polymyositis (PM), as well as facioscapulohumeral muscular dystrophy (FSHD). The cells are administered via intravenous infusion and are intended to provide a systemic anti-inflammatory effect by regulating the immune response and promoting tissue repair.
- Brand names
- Restem-L
- Other names
- Umbilical Cord Lining Stem CellsUMPCsUmbilical Mesenchymal Progenitor Cells
Beyond the preview
Go deeper on Restem-L.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Restem-L.